The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
April 24th 2025
A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for Cancer Research annual meeting runs April 25-30, with the key presentations coming Sunday through Tuesday.
Targeting MACC1 Offers Promising Therapeutic Strategy for PAH
April 10th 2024Positive responses seen following experiments involving metastasis-associated in colon cancer 1 (MACC1) indicate that the biomarker can be used to better diagnose and treat patients with pulmonary arterial hypertension (PAH).
Read More
Study: Decreased BMI Increases Severe Exacerbation, All-Cause Mortality Risk in Patients With COPD
April 10th 2024Decreased body mass index (BMI) in patients with chronic obstructive pulmonary disease (COPD) was linked to a higher risk of severe exacerbations and all-cause mortality, emphasizing the importance of monitoring BMI for managing COPD and predicting outcomes.
Read More
Nirogacestat Linked With Improved Functional Status in Patients With Desmoid Tumors
April 9th 2024Results presented at the National Community Oncology Dispensing Association International Spring Forum describe meaningful improvements in functioning among patients who received the oral gamma secretase inhibitor to treat progressing desmoid tumors.
Read More
In AML, CAR T-Cell Therapy Has Higher CR Rate After Transplant
April 8th 2024In this investigation, investigators sought insights into the safety and efficacy of chimeric antigen receptor (CAR) T-cell therapy in acute myeloid leukemia (AML), with a particular focus on how various patient subgroups fared for complete remission (CR).
Read More
Dr Krystyn Van Vliet on Tackling Scalability, Cost When Using 3D Platforms for MS Drug Discovery
April 7th 2024Krystyn Van Vliet, PhD, of Cornell University, discusses the scalability of 3D platforms in multiple sclerosis (MS) drug discovery and compares their costs with those of other drug discovery methods.
Watch
Dr Raajit Rampal Discusses Disease Modification and Emerging Therapies in Polycythemia Vera
April 7th 2024Raajit Rampal, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the potential of a disease-modifying therapy in polycythemia vera, treating high-risk vs low-risk patients, and emerging therapies in the pipeline.
Watch
FDA Approves Cilta-Cel for Earlier Treatment of RRMM
April 6th 2024Most recently, the FDA’s Oncologic Drugs Advisory Committee unanimously voted to recommend ciltacabtagene autoleucel (Carvykti; Johnson & Johnson) in patients who have received at least 1 line of treatment for relapsed/refractory multiple myeloma (RRMM).
Read More
Dr Michael Morse Discusses Current HCC Treatment Strategies and Future Directions
April 5th 2024Michael Morse, MD, FACP, MHS, professor of medicine at Duke University School of Medicine and medical oncologist at Duke Cancer Center, spoke to the evolution of hepatocellular carcinoma (HCC) treatment in recent years, as well as ongoing research with potential to impact clinical practice.
Watch
Study: Patients With SLE, AF Experience Higher In-Hospital Mortality Rate
April 5th 2024Patients with systemic lupus erythematosus (SLE) and atrial fibrillation (AF) exhibited elevated risks of severe cardiac complications, alongside increased in-hospital mortality, costs, and length of stay (LOS).
Read More
Trends in Low-Value Cancer Care During the COVID-19 Pandemic
Among adults with newly diagnosed cancer, rates of low-value cancer services persisted throughout the COVID-19 pandemic in areas ranging from peridiagnosis imaging to end-of-life care.
Read More
Indirect Comparison Finds Bimekizumab More Effective Than Guselkumab in Psoriatic Arthritis
April 4th 2024Patients included in the analysis had psoriatic arthritis and had either not been treated with biologic disease-modifying antirheumatic drugs or had an inadequate response or an intolerance to tumor necrosis factor inhibitors.
Read More
The newest treatment approved for amyotrophic lateral sclerosis (ALS) will be withdrawn from the market due to negative clinical trial results; former President Trump’s surgeon general is advocating for conservative states to support needle exchanges; new US hepatitis C infections dropped slightly in 2022 after more than a decade of steady increases.
Read More